Skip to main content

This page is intended for UK healthcare professionals and other relevant decision makers only. If you are a member of the public, please click here.

This portal is funded and owned by Novartis Pharmaceuticals UK Ltd and includes content approved by Novartis.

Adverse events reporting information can be found in the footer of this page.

Novartis Pro UK

Main navigation

    Menu
  • Medicines
    • Cardio-metabolic
      • LEQVIO®▼ (inclisiran)
    • Dermatology
    • Haematology
      • FABHALTA®▼ (iptacopan)
      • JAKAVI® (ruxolitinib)
      • SCEMBLIX®▼ (asciminib)
    • Immunology
    • Neuroscience
      • AIMOVIG® (erenumab)
      • KESIMPTA®▼ (ofatumumab)
    • Oncology
      • KISQALI® (ribociclib)
      • TAFINLAR® (dabrafenib) + MEKINIST® (trametinib) in melanoma
      • SANDOSTATIN® LAR® (octreotide acetate)
    • Respiratory and Inflammation
    • Rheumatology
      • COSENTYX® (secukinumab)
  • Therapy Areas
    • Cardio-metabolic
    • Dermatology
    • Haematology
    • Immunology
    • Neuroscience
    • Oncology
    • Respiratory and inflammation
    • Rheumatology
  • Events
  • Resources
  • Healthcare Systems Support
    • Disease area service resources
      • Service resources: Oncology
      • Breast Cancer Inequalities Tool
    • Collaborative Working
    • Contact us
Login
What are you looking for?
top

Resources

  • Print
  • PDF

The content on this page is currently unavailable.

 

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard. Adverse events should also be reported to Novartis online through the pharmacovigilance intake (PVI) tool at www.novartis.com/report, or alternatively email [email protected] or call 01276 698370.

  • Print
  • PDF

Novartis Pharmaceuticals UK Limited is a limited liability company registered in England and Wales under number 119006.


Registered office: The WestWorks Building, White City Place, 195 Wood Lane, London, W12 7FQ.

UK | March 2025 | FA-11207513-2
 

Explore the Site
  • Medicines
  • Therapy areas
  • Events
  • Resources
  • Healthcare Systems Support
Helpful Links
  • Privacy Notice
  • Terms of Use
  • Accessibility
  • Contact us

© 2025 Novartis Pharmaceuticals UK Limited. All rights reserved.

people chatting in the office

Welcome to Pro.Novartis.com

The Novartis portal for UK healthcare professionals (HCPs) and other relevant decision makers* is where you can find promotional information about Novartis products, therapy area materials and professional resources.

*Other relevant decision makers particularly includes those with an NHS role who could influence in any way the administration, consumption, prescription, purchase, recommendation, sale, supply or use of any medicine but who are not health professionals.

I am a UK healthcare professional and/or an NHS professional involved in service or budgetary planning responsibilities
I am a member of the public
people chatting in the office

Welcome to Pro.Novartis.com

The Novartis portal for UK healthcare professionals (HCPs) and other relevant decision makers* is where you can find promotional information about Novartis products, therapy area materials and professional resources.

*Other relevant decision makers particularly includes those with an NHS role who could influence in any way the administration, consumption, prescription, purchase, recommendation, sale, supply or use of any medicine but who are not health professionals.

I am a UK healthcare professional and/or an NHS professional involved in service or budgetary planning responsibilities
I am a member of the public